FAST NEWS: Clover Bio Gets Exclusive Rights for Imported Flu Vaccine
The latest: Clover Biopharmaceuticals Ltd. (2197.HK) said on Monday it has reached an exclusive agreement to import Adimmune Corp.’s quadrivalent seasonal influenza vaccine AdimFlu-S (QIS) to China. It added it will…
RELATED ARTICLES
-
With healthier finances, Clover Bio shifts to flu and RSV vaccines
2197.HK
- Health Guard plans dual listing to fund HPV vaccine fight
-
FAST NEWS: Clover Bio slumps after booting from China-Hong Kong Stock Connect
2197.HK
-
Fosun Pharma, CanSino take different paths as Covid lift fade
2196.HK 6185.HK
- China’s mRNA pioneer Stemirna faces post-Covid reinvention test
-
FAST NEWS: Simcere gets exclusive rights to innovative influenza drug
2096.HK
-
FAST NEWS: CanSino receives Gates Foundation grant to develop polio vaccine
6185.HK 688185.SHG
Discover hidden China stock gems in our weekly newsletter